Eidos Therapeutics Inc
(EIDX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2016 | |
| Cash Flows From Operating Activities | |
| Net Income | -2,540 |
| Depreciation Amortization | 1 |
| Other Working Capital | 200 |
| Other Operating Activity | 289 |
| Operating Cash Flow | $-2,050 |
| Cash Flows From Investing Activities | |
| Investing Cash Flow | $0 |
| Cash Flows From Financing Activities | |
| Other Financing Activity | 3,990 |
| Financing Cash Flow | $3,990 |
| Beginning Cash Position | 20 |
| End Cash Position | 1,950 |
| Net Cash Flow | $1,930 |
| Free Cash Flow | |
| Operating Cash Flow | -2,050 |
| Free Cash Flow | -2,050 |